Patrick Hanafin A mechanism-based model (MBM) for characterizing bidirectional interdependent bacteriophage (phage)-bacteria interactions guided by in vitro and animal PK/PD studies
|
Luke Fostvedt Integrated Parent/Metabolite Population PK Model of Abrocitinib to Support Dose Recommendations
|
PK/PD Studies of Selective PDE3, PDE4, and PDE7 Inhibitors in a Mouse Model of Autoimmune Hepatitis
|
Pharmacokinetics of 200 mg Ritlecitinib after Single and Multiple Oral Administrations in Healthy Chinese Adults and Comparison in Asian and Western Population
|
Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients With Osteoarthritis of Hip and Knee
|
Ahmed Salem Model-Based Approach to Identify Predictors for Weekly Paclitaxel-Induced Myelosuppression Using Real-World Data
|
Ryota Jin Analysis of Long-term Progression of Parkinson's Disease and Covariate Effects of Sex and LRRK2-Associated Single Nucleotide Polymorphisms (SNPs) by SReFT
|
Brian Maas Predicting RSV Efficacy for MK-1654 During Post-COVID-19 Pandemic RSV Seasons with Protracted Transmission Pattern using MBMA and Clinical Trial Simulation Approaches that Account for RSV Force-of-Infection
|
Anders Thorsted An integrated model for red blood cells, reticulocytes, hemoglobin, platelets, erythropoietin, and thrombopoietin – Exploration of altered hematopoiesis following administration of an anti-Oncostatin M antibody
|
Li Zhang Population Pharmacokinetics of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
|
Every heart matters: adaptation of a tacrolimus model to inform tacrolimus therapy using the PRIOR approach
|
Jacob Leander Stochastic mixed effects modeling of home-measured peak expiratory flow and the association to exacerbation risk in asthma
|
Time-Matched, Linear Mixed-Effects Analysis of the Concentration-QT Relationship of Single-Agent Encorafenib in Patients With Unresectable or Metastatic BRAF V600-Mutant Melanoma or Metastatic Colorectal Cancer
|
Time-Matched, Linear Mixed-Effects Analysis of the Concentration-QT Relationship of Single-Agent Binimetinib in Patients With Cancer and Healthy Volunteers Pooled Across Multiple Studies
|
Population Pharmacokinetic Analysis of Encorafenib and Binimetinib in Patients With Unresectable or Metastatic BRAF V600-Mutant Melanoma
|
Model-Based Characterization of Tumor Dynamics in Patients With Melanoma Treated With Encorafenib + Binimetinib in the COLUMBUS Study
|
Joy Hsu Population Pharmacokinetics of Atezolizumab in Combination with Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Patients with Metastatic Melanoma
|
Diego Vera Towards a mechanistic modelling platform to support development of new treatments in acute intermittent porphyria
|
Nicolás Marco-Ariño The broad use of pharmacometrics in patient care: the case of blood transfusion and perioperative management
|
Andrew SyBing Determining an appropriate Tacrolimus dosage regimen in Hispanic renal transplant patients
|
Daniel Rosenbloom Population pharmacokinetic analysis of elbasvir/grazoprevir (EBR/GZR) for pediatric dose selection to treat chronic hepatitis C (HCV) for adolescents
|
Exposure-Response Analysis of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma (uHCC)
|
Megan Cala A Mixed-Effects Approach to Modeling Progression Characteristics of the modified Friedreich’s Ataxia Rating Scale (mFARS) in Friedreich’s Ataxia
|
Exposure-Response (E-R) Analyses of Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, to Inform Dose Selection for a Phase 3 Trial in Non-Small Cell Lung Cancer (NSCLC)
|
Population pharmacokinetic model of AST-001 combining endogenous production and exogenous administration in healthy subjects
|
Zhaoyu (Amy) Meng Population Pharmacokinetic Analysis of Filgotinib and its Metabolite GS-829845 in Healthy Subjects and Subjects with Rheumatoid Arthritis
|
Jos Lommerse Children are not small adults, but are preterm neonates just smaller babies? A cautionary tale against off-label use of raltegravir in preterm neonates
|
Matts Kaagedal Population Pharmacokinetics Of The Port Delivery System With Ranibizumab (PDS) Supporting Long Durability Of Release From The Implant Into The Vitreous Of The Eye
|
Elena Vasileva Semi-mechanistic PK/PD modeling of anti-CD47 therapeutic agent
|
L Bao Assessment of the Impact of Anti-Drug Antibody (ADA) on Population Pharmacokinetic Modeling
|
Joao Abrantes Model-informed development of RG6102, an amyloid-targeting investigational drug with enhanced brain penetration properties
|
Chiara Zecchin Probability Of Pharmacological Success To Expedite Decision Making In Clinical Development
|
Nastya Kassir Exposure-Response Analysis of Etrolizumab in Patients with Moderately-to-severely Active Ulcerative Colitis
|
Longitudinal Discrete Time Markov Model describes Gastrointestinal Adverse Events from bispecific antibody for Fibroblast Growth Factor Receptor 1/βKlotho Complex in humans
|
A Framework to Simulate Biologically Relevant Survival Data in Oncology Patients with Confounded Exposure-Response Relationship
|
Time-to-event modelling of recurrent ischemic stroke during different time intervals after index ischemic stroke in Malaysian population.
|
Population Pharmacokinetics of Vancomycin in Pregnant Females
|
RPEM - The Randomized Parametric Expectation Maximization Algorithm
|
Population Pharmacokinetic Modeling for the Antibody-Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
|
Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin
|
Celine Laffont Modelling Buprenorphine Effect on Fentanyl-induced Respiratory Depression in Opioid-naïve and Opioid-tolerant Subjects
|
Satyaprakash Nayak Application of population PK and PK/PD modeling to predict dosing regimens in an adolescent population with severe hemophilia under treatment with an aTFPI (anti Tissue Factor Pathway Inhibitor) monoclonal antibody
|
Application of Population Pharmacokinetic Modeling to Support Modifications of USPI for Raltegravir Chewable Tablet Administered as Crushed Form to HIV Infected Pediatric Patients
|
Violeta Rodriguez Romero Evaluating Ontogeny to Guide Dose Selection in Pediatric Subjects
|
Juan Morales Joint modeling of longitudinal and survival data to find subject features influencing the likelihood of eventual type 1 diabetes diagnosis
|
Anita Moein Population Pharmacokinetic Analysis of Etrolizumab in Patients with Moderately-to-Severely Active Ulcerative Colitis
|
Aymara Sancho Araiz Semi-mechanistic model for the antitumor response of a combination cocktail of immune-modulators in non-inflamed (cold) tumors
|
Yue Zhao Quantitative Assessment of Immunogenicity Impact on Efficacy and Safety of a Nivolumab /Ipilimumab Combination in 1L Non-small Cell Lung Cancer.
|
Dawoon Jung Pharmacokinetics of Anti-SARS-CoV-2 Human Convalescent Plasma in High-risk Children
|
Dawoon Jung Pharmacokinetics of JSP191 in Severe Combined Immunodeficiency, Myelodysplastic Syndrome, and Acute Myeloid Leukemia Patients
|
Augmenting the utility of PBPK models using machine learning
|
Panteleimon Mavroudis A Multi-model approach for understanding anti-TGFb antibody for the treatment osteogenesis imperfecta.
|
Aline Barth Probability of Pharmacological Success of Gepotidacin in Japanese Subjects with Uncomplicated Urinary Tract Infections due to Escherichia coli
|
Aline Barth Population Pharmacokinetics of Gepotidacin in Healthy Subjects and Patients with Uncomplicated Urinary Tract Infections or Gonorrhea Following Oral Administration
|
Aline Barth Assessing Safety and Efficacy to Determine the Gepotidacin Probability of Pharmacological Success in Urogenital Gonorrhea
|
Yash Gandhi Comparative analysis of programmed cell death protein-1 (PD-1) target engagement of dostarlimab and pembrolizumab (pembro) in patients with advanced solid tumors using ex vivo interleukin 2 (IL-2) stimulation data
|
Yash Gandhi Population pharmacokinetics (PopPK) and exposure–response (ER) analysis of the anti-programmed cell death-1 receptor (PD-1) monoclonal antibody (mAb) dostarlimab in recurrent/advanced solid tumors with mismatch repair-deficiency (dMMR)
|
Scores of Health-Related Quality of Life Questionnaire Worsen Consistently in Patients with COPD: Estimating Disease Progression over 30 Years by SReFT with Individual Data Collected in SUMMIT Trial
|
Donald Lee A Pharmacokinetics Model for Rifampin Exposures in Human Bone Using PET Imaging
|
Prediction of overall survival for different lines of NSCLC therapy using joint modeling with nonlinear SLD dynamics
|
Josiah Ryman Modeling the Time-Varying Impacts of Immunogenicity on Pharmacokinetics and Efficacy
|
Lindsay Clegg A Linear Mixed Effect Model of Disease Progression and Dapagliflozin Effects on Estimated Glomerular Filtration Rate Slope in Chronic Kidney Disease, Type 2 Diabetes Mellitus, and/or Heart Failure
|
Rob Christiaan van Wijk Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19
|
A library of parent-metabolite models for the MonolixSuite
|
Jenny Chien A Quantitative Modelling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal Antibodies to Advance Bamlanivimab into a First-in-Human Clinical Trial
|
Keagan Collins Longitudinal Mixed-Effects Model for Urine-Albumin-to-Creatinine-Ratio in Early Kidney Transplant Recipients
|
Assessing the Impact of Target Biological Half-Life and Drug-Target Binding Kinetics on Efficacy: An Application in Model-Based Target Pharmacology Assessment
|
Florencio Serrano Castillo Longitudinal Exposure-Response (ER) Model of Glucagon-like peptide-1 (GLP-1) analogs for weight management
|
Pratik Bhagunde Modeling and Simulation to Support First-in-Human Dose Selection for SAR442257 (Anti-CD38/CD28/CD3 Trispecific Antibody)
|
Population pharmacokinetics of dapagliflozin in adults with chronic kidney disease vs. adults with type 2 diabetes mellitus
|
Azar Shahraz Population Pharmacokinetics Analysis of AZD0171, an Anti-LIF Antibody in Patients with Advanced Solid Tumors
|
Population Pharmacokinetic/Pharmacodynamic Modeling of GSK3228836, a 2’MOE Modified Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B (CHB)
|
Peter Chang Population Pharmacokinetics of Mavacamten in Adults with Obstructive Hypertrophic Cardiomyopathy (oHCM)
|
David Salinger Exposure-Response Modeling of Mavacamten in Adults with Obstructive Hypertrophic Cardiomyopathy (oHCM)
|
Yue Gao Population Pharmacokinetic Analysis of Dupilumab in Children 6 to <12 Years of Age with Asthma
|
Christine Xu Empirical Exposure-Response (E-R) Modeling of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
|
Farzaneh Maleki Characterization of Time-Course of Neutrophil After Repeated Oral Administration of Brepocitinib Using a Semi-mechanistic Model
|
An integrated population pharmacokinetic model of nanoparticle albumin-based paclitaxel and its metabolites after pressurized intraperitoneal aerosol chemotherapy (PIPAC) administration
|
Manasa Tatipalli Model-informed optimization of a pediatric clinical pharmacokinetic trial of a new spironolactone liquid formulation
|
Sebastien Bihorel Population Pharmacokinetics Analysis for Molnupiravir in Adults With COVID-19
|
Po-Wei Chen Evaluation of Migraine-Specific Questionnaire (MSQ) to Inform Migraine Drug Development Using Item Response Theory Modeling
|
Oleg Milberg A Semi-mechanistic PK/PD Model for First in Human Dose Selection of mRNA-3745, an Investigational Messenger RNA Therapeutic Encoding Human Glucose-6-Phosphatase Enzyme for the Treatment of Glycogen Storage Disease Type-1a
|
Evaluation of Dosing Regimen of Artemether/Lumefantrine in Pregnant Women Using Population PK Model
|
Ari Pritchard-Bell Methods for Estimating Impact of Neonatal Fc Receptor Binding on Monoclonal Antibody Pharmacokinetics for First-in-Human Prediction
|
Camila de Almeida Smallpox: How to define an efficacious dose for an eradicated disease?
|
Bart Borek Considerations For Exposure-Response Analyses When Transitioning From Standard Of Care
|
Allison Dunn Identifying Risk Factors for Poor Clinical Outcomes in Pediatric Hematopoietic Stem Cell Transplant Patients Receiving Busulfan using Time-to-Event Modeling
|
Ayyappa Chaturvedula Population pharmacokinetic model for tenofovir/emtricitabine and their intracellular metabolites in transgender women
|
Soha Freidy A pharmacokinetic (PK) model for evaluating pulmonary exposure of bacteriophage (phage) therapy following intravenous (IV) and intratracheal (IT) administration
|
Tae Kyu Chung A mechanism-based pharmacokinetic-pharmacodynamic model to evaluate the effect of YH4808, a novel K+ competitive acid blocker, on the increase in intragastric pH
|
Jackson Burton Development of disease progression models in Huntington’s disease as a basis for a clinical trial simulation
|